All In MedTech

Device Trial Radar · NCT05409976

The GORE® VIABAHN® FORTEGRA Venous Stent IVC Study

Evaluation of the GORE® VIAFORT Vascular Stent for Treatment of Symptomatic Inferior Vena Cava Obstruction With or Without Combined Iliofemoral Obstruction

Last checked: Nov 20, 2026Latest source record: Aug 27, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingResults posted on the registry

Status

Active, not recruiting

Enrollment

136

Actual

Start

Oct 25, 2022

Primary completion

May 9, 2026

Study completion May 9, 2030

Sponsor

Lead sponsor
W.L.Gore & AssociatesNot on our public-company list
Sponsor type
Industry
First posted
Jun 8, 2022

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated device
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective, multicenter, non-randomized, single-arm study to evaluate the performance, safety, and efficacy of the GORE® VIABAHN® FORTEGRA Venous Stent (formerly known as GORE® VIAFORT Vascular Stent) for treatment of symptomatic inferior vena cava obstruction with or without combined iliofemoral obstruction in adult patients.

Conditions

  • Venous Thromboses
  • Venous Disease
  • Venous Leg Ulcer
  • Venous Stasis
  • Venous Ulcer
  • Venous Stenosis
  • Venous Occlusion
  • Vein Thrombosis
  • Vein Occlusion
  • Vein Disease

Interventions

  • GORE® VIAFORT Vascular StentDevice

    Treatment of symptomatic IVC obstruction with or without combined iliofemoral obstruction with the GORE® VIAFORT Vascular Stent.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Initial Subject Analysis Population: Percentage of Subjects With Freedom From the Composite Endpoint of Effectiveness and Safety EventsTime frame: 12 months
  2. Global Analysis Population: Percentage of Subjects With Freedom From the Composite Endpoint of Effectiveness and Safety EventsTime frame: 12 months

Locations

17 sites in 7 countries. Site status is shown where the registry gives one.

  • Stanford University School of Medicine

    Stanford, California

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia

  • Northwestern

    Chicago, Illinois

14 more study sites with a free account

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.